for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval marks an important advancement in ...

For safety, the most common adverse effects (AEs) related to ensartinib included rash (67.8%), increased aspartate aminotransferase (37.8%), increased alanine aminotransferase (48.3%), pruritus (26.6% ...

Ensacove is approved for ALK-positive NSCLC patients who haven't received prior ALK-inhibitors, offering a new first-line treatment option. The eXALT3 trial showed Ensacove significantly improved ...

Opens in a new tab or window The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the ...

for the treatment of adults with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor. In the trial, 290 patients were ...

Data supplied by Morningstar and accurate on Sep 18, 2024. It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of ...